Get started
Senseonics Holdings, Inc.Senseonics Holdings, Inc.Senseonics Holdings, Inc.

Senseonics Holdings, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

SENS trade ideas

$SENS Breaks Out After Putting In Multiple Bottom$SENS is finally breaking to the upside after putting in multiple bottoms at the $.80 to $.90 level. Yesterday, $SENS put out news that we believe will continue to push the stock higher. As always, trade with caution and use protective stops. Good luck to all! --Cigna coverage decision adds more than 17 million covered lives for Eversense CGM-- GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Cigna is now providing coverage for the Eversense® CGM System, effective February 15, 2020. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider’s time for the in-office sensor placement. Cigna Corporation is a global health service company dedicated to improving the health, well-being, and peace of mind of those who they serve. Cigna has more than 17 million medical customers and offers a Medicare Advantage plan in 17 states and Washington DC. This most recent coverage decision – in addition to Aetna (AET), Humana, HCSC Blue Cross Blue Shield and other health insurance providers – adds to the growing list of payers enabling their members to benefit clinically from the long-term Eversense CGM System. “Cigna prides itself on providing choice and access to quality care through connected, personalized solutions that allow their members to harness actionable insights to drive better healthcare results. Now Cigna members will have the choice to use the only long-term implantable CGM system available to help them better manage their diabetes,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “Eversense provides actionable glucose data for users – not only where they are right now, but the direction they are headed. With superior accuracy, longest sensor life, on-body vibratory alerts and remote monitoring capability, users can proactively manage their glucose levels by treating their diabetes before they get to dangerously high or low levels. This information in the hands of the users allows them to manage their diabetes and experience healthier outcomes through personalized information and technology.” The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor. Eversense users now have the freedom to make treatment decisions based on their Eversense readings. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure. Patients who are interested in getting started on Eversense can sign up at www.eversensediabetes.com Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348). About Eversense The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see eversensediabetes.com About Senseonics Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
AMEX:SENS
by OptionsGains
Short squeeze possible in Senseonics Alerts et for a break above $1.38 for possible long entry 200ma acting as resistance very high short interest @ 33.48% Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.
AMEX:SENS
by RedHotStocks
SENS - Not Yet Out of the WoodsNote: This is not an investment advice but my opinion alone. Please feel free to comment. My last idea posted on SENS, I noted when it was at around $3.36 that is was forming an head and shoulder pattern and it was not looking good. I also mentioned further downturn was ahead. Now I feel we could still head down to around .60cents if it breaks the previous low of .79cents. The company needs cash and a raise is not out of the picture and maybe a RS at .60. Please do your DD.
AMEX:SENSShort
by UnknownUnicorn3272672
Senseonics bullish reversal Entry level above resistance $1.11 Target price $1.34. Bullish cross by 7&12 MA's above 34 MA Nice step up in volume. 34.35 % Short interest could begin to get squeezed. Company profile Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application. The company was founded on June 26, 2014 and is headquartered in Germantown, MD
AMEX:SENSLong
by Bullishcharts
SENS to Pop on Stifel $2 price target and Insider Buying======================== Senseonics Holdings, Inc. (SENS) Alert Price: $1.23 Float: 149.41 Chart Analysis Investor Presentation Price Target: $2.00 (Stifel) Company Website | Recent News ======================== Members, Act Fast, and get Senseonics Holdings, Inc. (SENS) on your screen and ready to trade. The last time we brought SENS to your attention, shares ran up over +30% in one session, and over +234% for the year! Shares on SENS have pulled back considerably since then, but we are predicting another epic bull run for this NYSE listed company. SENS Is Showing Us All The Signs Of A Company That Is Ready To Reverse Hard Off Its Lows And Start A Big Time Bull Rally: Heavy Insider Buying Analyst Upgrades Strong Revenue Growth Bullish Trending Chart About Senseonics Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone. About Eversense The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. Starting this fall, the system will be used to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements will still be required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. Company Highlights Disruptive, Highly-Innovative Technology in a Fast-Growing CGM Market with a 1 Significant Unmet Need Clinically Proven CGM System Providing Enhanced Patient Experience and 2 Clinical Outcomes Access to Key Global Markets with Increasing Coverage and Successful 3 Commercialization in Europe and the US 4 Robust Product Strategy and Deep Pipeline to Support Long-Term Growth Stifel Starts Senseonics Holdings (SENS) at Buy. Predicts Move Of +62% From Here Stifel analyst Mathew Blackman initiates coverage on Senseonics Holdings (NYSE: SENS) with a Buy rating and a price target of $2.00. The analyst comments "The SENS story is in the earliest of innings and not surprisingly, the company faces a number of commercialization challenges, most notably garnering broad reimbursement and high cash burn. Nonetheless, our thesis is straightforward: (1) we believe CGM is the most critical piece of the diabetes technology eco-system; (2) SENS' implantable sensor is differentiated and can appeal to patients averse to frequent sensor changes and other quality-of-life headwinds associated with fingersticks and current CGM systems; and (3) assuming a $5B+ CGM opportunity today (intensive-insulin), even if the ultimate Eversense patient cohort only appeals to 5% of the market, SENS revenue base should approximate $200M-300M, significantly higher than current valuation contemplates." SENS Announces a Positive Coverage Decision for Eversense CGM From Humana Two weeks ago, the Company announced that Humana is now providing coverage for the Eversense CGM System and insertion procedure, effective October 22, 2019. Under the Humana coverage policy patients with both type 1 diabetes and type 2 diabetes that require insulin are eligible for coverage for Eversense. Humana is the fifth largest health insurer in the US covering 17 million patients across all 50 states, Washington DC and Puerto Rico. “Eversense and the insertion procedure being included in the Humana CGM policy once again validates that an increasing number of payers are supporting the value our long-term CGM provides to patients with diabetes,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “We are especially pleased that access has been included for not only for the type 1 diabetes patients but also for the type 2 patients that require insulin. We are confident that Eversense can conveniently assist all patients in managing their diabetes.” The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts when high or low glucose thresholds are crossed and can be removed, recharged and re-adhered without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure. Heavy Insider Buying Tells A Story Of A Grossly Undervalued Company Over the past 12-months SENS insiders have made a total of 26-insider buys and ZERO insider sells! President and CEO of Senseonics Holdings Inc Timothy T Goodnow bought 88,500 shares of SENS on 09/09/2019 at an average price of $1.10 a share. The total cost of this purchase was $97,350. A large purchase like that should give potential SENS buyers a strong sense of confidence heading into the trade. It is quite obvious that SENS management believes that the Company's stock is undervalued at these current levels. Not that long ago, shares of SENS were trading at double than what they are now. We agree with the analyst's estimates, and believe it's just a matter of time before SENS is trading back above $2.00 Remember... The last time we were this bullish on SENS, shares ran up over +234%! SENS Is Addressing An Unmet Need In A $2B Market CGM Is The Fastest Growing Diabetes Technology Segment Globally Eversense Addresses Unmet Needs Long-term: sensor lasts up to 180 days Only needs to be switched 4x a year vs. 36x a year Fully implantable sensor On-body vibration alerts Accuracy Flexibility: removable transmitter Safety Adoption Strategy Differentiation Drive Demand from HCPs Patients Clinical Demonstration Patients Are Adopting Eversense Treatment At A Rapid Pace 85% Lead Increase from March 1 - June 30, 2019 102% Prescription Increase from March 1- June 30, 2019 310% New Patient Shipment Increase from March 1 - June 30, 2019 550 HCPs Prescribed as of June 30, 2019 SENS Chart Forming A Golden Cross. We Anticipate A Nice Move From Here The golden cross is a technical chart pattern indicating the potential for a major rally. The golden cross is a candlestick pattern that is a bullish signal in which a relatively short-term moving average crosses above a long-term moving average. The golden cross is a bullish breakout pattern formed from a crossover involving a security's short-term moving average (such as the 15-day moving average) breaking above its long-term moving average (such as the 50-day moving average) or resistance level. Some of our biggest winners have had this exact same setup. We've done our very own chart analysis, and see the potential for a move of over +40% from today's alert price! The Bottom Line SENS may be one of the most undervalued companies trading on the NYSE at the moment. With its strong revenue growth and heavy insider buying, we are confident SENS will meet analysts $2.00 Price Target. Traders who are looking for +100% ROI should get SENS on their screens immediately! (*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.) Best Regards, Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report has not received compensation to complete this marketing campaign for SENS. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice. The issueres of this report placed $1,000 USD spread bet on SENS to go up, however does not own, but may acquire and then sell shares of SENS within the near future.
AMEX:SENSLong
by RedHotStocks
SENS, forming H&S PatternNote: This is not an investment advice but my opinion alone. Please feel free to comment. The chart for sens looks to be forming a Head and Should Pattern and we are currently in the right shoulder stage. With earnings already pre-announced and guidance low compared to consensus, I wouldn't be surprised to see a sell off after earnings this week. I had hoped the 5 year RSI would have gotten to oversold territory during the last sell off in October and that would have giving us a strong base of new buyers but that did not happen The recent run lead me to take a deeper look at the chart after having pre released lower than expected 2019 revenue guidance. I definitely hope all of the above is wrong that the stock actually heads higher as I have been long and continue to be long, but the current financial state of the company is negative.
AMEX:SENS
by UnknownUnicorn3272672
SENS Negative in the short termNote: This is not an investment advice but my opinion alone. Please feel free to comment. To be clear, I am long SENS and have been trading it as you can see from my chart. The stock hit a 52 week high after the FDA approval and is going through the ABC reversal. I believe it is on the last leg down which could take us between $2.20 to $2.50. This will put the stock in oversold territory and I will look to add more to my long position then.
AMEX:SENS
by UnknownUnicorn3272672